MERCK & CO., INC.

CPT · Copyright/Patent/Trademark

Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.

HCR · Health Issues

Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2026 National Defense Authorization Act, S.2296/H.R.3838/P.L.119-60), antimicrobial resistance, VICP Program, PBM reform, vaccine schedule and vaccine safety; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.

Literal federal measure citations: S.2296, H.R.3838, S.891

MMM · Medicare/Medicaid

General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.

Literal federal measure citations: H.R.1

TAX · Taxation/Internal Revenue Code

Issues related to tax reform; R&D tax credit; international taxation.

TRD · Trade (domestic/foreign)

Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals.